Intra-Cellular Therapies Inc expected to post a loss of 32 cents a share - Earnings Preview

Intra-Cellular Therapies

30/04/2024 15:29

* Intra-Cellular Therapies Inc  ITCI.OQ   ITCI.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 7 for the period ending March 31 2024
    * The New York City-based  company is expected to report a
48.3% increase in revenue to $141.358 million from $95.31
million a year ago, according to the mean estimate from 13
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Intra-Cellular Therapies
Inc
is for a loss of 32 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 2.4%
in the last three months. ​
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $91.00​, above​ its last closing price
of $72.30. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.44       -0.44      -0.30     Beat    32.2
 Sep. 30 2023  -0.56       -0.57      -0.25     Beat    55.8
 Jun. 30 2023  -0.59       -0.59      -0.45     Beat    23.8​
 Mar. 31 2023  -0.59       -0.61      -0.46     Beat    24.1
 ​​Dec.        -0.63       -0.59      -0.45     Beat    24
 31 2022                                                
 Sep. 30 2022  -0.82       -0.81      -0.57     Beat    30​
 Jan. 1 0001   -0.73       -0.76      -0.92     Missed  -21
 Mar. 31 2022  -0.97       -0.92      -0.78     Beat    15.3
 This summary was machine generated April 30 at 14:29 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)